Description
This modifier is used to indicate subsequent claims for a defined course of therapy, such as EPO, sodium hyaluronate, or infliximab, specifically in the context of end-stage renal disease (ESRD). It helps ensure appropriate billing and documentation for ongoing treatment regimens in patients with chronic kidney conditions.